Pinaverium bromide, bifico, and deanxit in treatment of diarrhea-predominant IBS and its effects on inflammatory factors and psychological state

Abstract

Objective To study the treatment effect of pinaverium bromide, bifico, and deanxit for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on inflammatory factors and psychological state. Methods 84 patients with diarrhea-predominant IBS were randomly divided into a routine group ( orally taking pinaverium bromide and bifico) and a triplet group (taking pinaverium bromide, bifico, and deanxit). The duration of treatment was 1 month. The treatment effects were compared between the two groups. Results After 1 month’s drug administration, the scores of abdominal discomfort and total score in the two groups were significantly decreased (P<0.05); and the scores in the triplet group were significantly lower than those in the routine group (P<0.05). The effective rate was 95.24% in the triplet group and 75.87% in the routine group (P<0.05). The levels of IFN-γ[(22.71±4.76) and (29.18±4.23), P<0.05], IL-8 [(3.26±0.57) and (3.96±0.65)], P<0.05], and IL-12 [(39.38±7.03) and (45.24±7.26), P<0.05] were significantly lower after than before the treatment in both groups(P<0.05). The SAS score [(51.30±7.48) and (56.44±8.13), (P<0.05)] and the SDS score [(54.98±3.52) and (60.51±4.07), (P<0.05)] of the two groups were significantly lower after than before the treatment (P<0.05). Conclusions Deanxit, pinaverium bromide, and bifico for diarrhea-predominant IBS can relieve the inflammatory response, improve the abdominal symptoms and psychological states, and enhance the treatment effect. Key words: Pinaverium bromide; Bifico; Deanxit; Combination; Diarrhea-predominant IBS; Efficacy; Self-rating anxiety and depression scores